Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Val Gebski »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Val Carr < Val Gebski < Val J. Gebski  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 6.
Ident.Authors (with country if any)Title
000124 (2017) Roberto Sorio [Italie] ; Célia Roemer-Becuwe [France] ; Felix Hilpert [Allemagne] ; Emma Gibbs [Australie] ; Yolanda García [Espagne] ; Janne Kaern [Norvège] ; Manon Huizing [Belgique] ; Petronella Witteveen [Pays-Bas] ; Flora Zagouri [Grèce] ; David Coeffic [France] ; Hans-Joachim Lück [Allemagne] ; Antonio González-Martín [Espagne] ; Gunnar Kristensen [Norvège] ; Charles-Briac Levaché [France] ; Chee Khoon Lee [Australie] ; Val Gebski [Australie] ; Eric Pujade-Lauraine [France]Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
000211 (2017) Eric Pujade-Lauraine [France] ; Jonathan A. Ledermann [Royaume-Uni] ; Frédéric Selle [France] ; Val Gebski [Australie] ; Richard T. Penson [États-Unis] ; Amit M. Oza [Canada] ; Jacob Korach [Israël] ; Tomasz Huzarski [Pologne] ; Andrés Poveda [Espagne] ; Sandro Pignata [Italie] ; Michael Friedlander [Australie] ; Nicoletta Colombo [Italie] ; Philipp Harter [Allemagne] ; Keiichi Fujiwara [Japon] ; Isabelle Ray-Coquard [France] ; Susana Banerjee [Royaume-Uni] ; Joyce Liu [États-Unis] ; Elizabeth S. Lowe [États-Unis] ; Ralph Bloomfield [Royaume-Uni] ; Patricia Pautier [France]Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
000357 (2017) Harpreet S. Wasan [Royaume-Uni] ; Peter Gibbs [Australie] ; Navesh K. Sharma [États-Unis] ; Julien Taieb [France] ; Volker Heinemann [Allemagne] ; Jens Ricke [Allemagne] ; Marc Peeters [Belgique] ; Michael Findlay [Nouvelle-Zélande] ; Andrew Weaver [Royaume-Uni] ; Jamie Mills [Royaume-Uni] ; Charles Wilson [Royaume-Uni] ; Richard Adams [Royaume-Uni] ; Anne Francis [Royaume-Uni] ; Joanna Moschandreas [Royaume-Uni] ; Pradeep S. Virdee [Royaume-Uni] ; Peter Dutton [Royaume-Uni] ; Sharon Love [Royaume-Uni] ; Val Gebski [Australie] ; Alastair Gray [Royaume-Uni] ; Guy Van Hazel [Australie] ; Ricky A. Sharma [Royaume-Uni]First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
000C61 (2015) Chee Khoon Lee [Australie] ; Sarah Lord [Australie] ; Tami Grunewald [Australie] ; Val Gebski [Australie] ; Anne-Claire Hardy-Bessard [France] ; Jalid Sehouli [Allemagne] ; Kathrine Woie [Norvège] ; Mark Heywood [Canada] ; Christian Schauer [Autriche] ; Ignace Vergote [Belgique] ; Giovanni Scambia [Italie] ; Annamaria Ferrero [Italie] ; Philipp Harter [Allemagne] ; Eric Pujade-Lauraine [France] ; Michael Friedlander [Australie]Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
000E54 (2015) Trevor Leong [Australie] ; B Mark Smithers ; Michael Michael [Australie] ; Val Gebski [Australie] ; Alex Boussioutas [Australie] ; Danielle Miller [Australie] ; John Simes [Australie] ; John Zalcberg ; Karin Haustermans [Belgique] ; Florian Lordick [Allemagne] ; Christoph Schuhmacher [France] ; Carol Swallow ; Gail Darling ; Rebecca WongTOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
001E10 (2010) Eric Pujade-Lauraine [France, Allemagne, Suède, Australie, Canada, Autriche, Belgique, Italie, Norvège] ; Uwe Wagner ; Elisabeth Aavall-Lundqvist ; Val Gebski ; Mark Heywood ; Paul A. Vasey ; Birgit Volgger ; Ignace Vergote ; Sandro Pignata ; Annamaria Ferrero ; Jalid Sehouli ; Alain Lortholary ; Gunnar Kristensen ; Christian Jackisch ; Florence Joly ; Chris Brown ; Nathalie Le Fur ; Andreas Du BoisPegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

List of associated KwdEn.i

Nombre de
documents
Descripteur
5Humans
4Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
4Female
4Middle Aged
3Adult
3Aged
3Aged, 80 and over
3Disease-Free Survival
3Ovarian Neoplasms (drug therapy)
2Antineoplastic Agents (therapeutic use)
2Antineoplastic Combined Chemotherapy Protocols (adverse effects)
2Doxorubicin (administration & dosage)
2Doxorubicin (analogs & derivatives)
2Neoplasm Recurrence, Local (drug therapy)
2Paclitaxel (administration & dosage)
2Polyethylene Glycols (administration & dosage)
2Treatment Outcome
1Adolescent
1Age Factors
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic agent
1Bevacizumab (administration & dosage)
1Bevacizumab (adverse effects)
1Cancerology
1Carboplatin
1Carboplatin (administration & dosage)
1Carboplatin (adverse effects)
1Chemoradiotherapy, Adjuvant (methods)
1Cisplatin (administration & dosage)
1Cisplatin (therapeutic use)
1Colorectal Neoplasms (pathology)
1Combined Modality Therapy
1Comparative study
1Double-Blind Method
1Doxorubicin
1Doxorubicin (adverse effects)
1Drug Resistance, Neoplasm
1Epirubicin (administration & dosage)
1Epirubicin (therapeutic use)
1Esophagogastric Junction (drug effects)
1Esophagogastric Junction (pathology)
1Esophagogastric Junction (radiation effects)
1Fluorouracil (administration & dosage)
1Fluorouracil (therapeutic use)
1Genes, BRCA1
1Genes, BRCA2
1Human
1Hypertension (chemically induced)
1Hypertension (physiopathology)
1Late
1Liposome
1Liver Neoplasms (drug therapy)
1Liver Neoplasms (radiotherapy)
1Liver Neoplasms (secondary)
1Maintenance Chemotherapy
1Male
1Mutation
1Neoplasm Recurrence, Local (surgery)
1Ovarian Neoplasms (genetics)
1Ovarian Neoplasms (pathology)
1Ovarian Neoplasms (surgery)
1Ovary cancer
1Paclitaxel
1Paclitaxel (adverse effects)
1Patient Selection
1Pegylated form
1Perioperative Care
1Phthalazines (therapeutic use)
1Piperazines (therapeutic use)
1Platinum Compounds
1Polyethylene Glycols (adverse effects)
1Preoperative Care
1Prognosis
1Radiotherapy, Adjuvant
1Relapse
1Stomach Neoplasms (drug therapy)
1Stomach Neoplasms (radiotherapy)
1Stomach Neoplasms (surgery)
1Survival Analysis
1Survival Rate
1Tablets
1Topotecan (administration & dosage)
1Young Adult

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Val Gebski" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Val Gebski" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Val Gebski
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024